Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma

Author(s): Priti Patel, Sandy Srinivas

Journal Name: Current Clinical Pharmacology
Continued as Current Reviews in Clinical and Experimental Pharmacology

Volume 6 , Issue 3 , 2011

Become EABM
Become Reviewer
Call for Editor


The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are associated with toxicities. The most common toxicities seen with the VEGF inhibitors are hypertension, fatigue, and hand- foot syndrome. The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management.

Keywords: Advanced renal cell carcinoma, targeted drugs, toxicity, mechanism, Hypertension, Proteinuria, Cardiotoxicity, Gastrointestinal Toxicities, Arterial Thrombosis, Hepatic Toxicities, Pulmonary Toxicity

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [181 - 188]
Pages: 8
DOI: 10.2174/157488411797189442
Price: $65

Article Metrics

PDF: 19